Amplia Therapeutics (ASX: ATX) has confirmed that an additional patient in the company’s ACCENT trial in pancreatic cancer has recorded a confirmed partial response.
The patient is participating in the company’s Phase 2a clinical trial investigating narmafotinib in the treatment of advanced pancreatic cancer (the ACCENT trial).
Combined with the three responses announced on 25 July, this total of four responders means only two more confirmed responses are required in this first of two patient cohorts
The ACCENT trial protocol requires that six of the 26 patients enrolled in the first cohort achieve this response level for the trial to continue with enrolment of an additional 24 patients
The trial explores the activity of narmafotinib, in combination with standard-of-care chemotherapy, in advanced pancreatic cancer patients.
A total of 50 patients are planned for the Phase 2a ACCENT trial, recruited in two cohorts.
The formal term ‘confirmed partial response’ means in these patients there is at least a 30% decrease in the overall size of tumour lesions, with no new tumour lesions, sustained over a two-month period, while a confirmed complete response refers to a total absence of tumour lesions over a two-month period.
“The activity of narmafotinib in the ACCENT trial continues to be very positive, consistent with our previous clinical and preclinical data. We remain on track to complete the interim analysis by the end of this quarter,” Amplia CEO and MD, Dr Chris Burns, said.
